Boehringer Ingelheim slashing 600 staffers as sales slide

The bloodletting in Big Pharma continues with news today that Boehringer Ingelheim is planning between 500 and 600 job cuts in its home country of Germany. The cuts come just a few weeks after the company announced its sales had dropped 3% in the first 6 months of the year and that full-year results would likely be down slightly from last year. The company plans to complete the layoffs by the end of 2016, reducing costs in Germany by 15%, or about €450 million ($580 million), according to a statement acquired by Reuters. About 14,000 of Boehringer's total workforce of 47,500 are employed in Germany. Story

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.